18th Jun 2020 17:59
Synairgen PLC - respiratory drug discovery company - Expands placebo-controlled home setting clinical trial of SNG001 in patients with Covid-19. Trial has been expanded beyond the Southampton area to include patients across the majority of the UK. Home setting arm of Synairgen's SG016 trial aims to recruit 120 patients who are either aged 65 or over, or are aged 50 and over with a high-risk comorbidity such as cardiovascular disease, diabetes or a chronic lung condition.
Current stock price: 39.50 pence
Year-to-date change: up more than 100%, 5.88 pence on January 2.
By Tapan Panchal; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Synairgen